<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1433">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142501</url>
  </required_header>
  <id_info>
    <org_study_id>HD-COVID-IR-EU</org_study_id>
    <nct_id>NCT05142501</nct_id>
  </id_info>
  <brief_title>Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy</brief_title>
  <acronym>COVID-thIRd</acronym>
  <official_title>Observation of Humoral and Cellular Immune Response After Additional Vaccine Dose With Different COVID-19 Vaccines in ESKD Patients in Hemodialysis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observation of humoral and cellular immune response after additional dose vaccine with&#xD;
      different COVID-19 vaccines in ESKD patients in hemodialysis therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open, prospective, observational trial the humoral and cellular immune response in&#xD;
      ESKD patients undergoing hemodialysis shall be analyzed after administration of a third dose&#xD;
      of vaccine. The total follow-up time per patient is up to 12 months after the third dose of&#xD;
      vaccine. In total, 340 patients (170 patients per country) shall be included. Only adult&#xD;
      patients capable of giving consent will be enrolled. The humoral immune response will be&#xD;
      analyzed in all patients, whereas the analysis of the cellular immune response will only be&#xD;
      conducted in 15% of the enrolled patients.&#xD;
&#xD;
      The HD-COVID-IR-EU study shall be conducted in Portugal and in Russia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral immune response</measure>
    <time_frame>12 months after start of study</time_frame>
    <description>The humoral immune response will be assessed at four different timepoints (Sample 1: prior to the third vaccine dose; sample 2: 1 months after the third vaccine dose; sample 3: 6 months after the third vaccine dose; sample 4: 12 months after the third vaccine dose or max. 4 weeks prior to the fourth vaccine dose, whichever comes first) through the measurement of the titers of Bioplex IgG antibody panel in study participant's blood samples.</description>
  </primary_outcome>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>COVID-19</condition>
  <condition>Hemodialysis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Four consecutive blood sampling throughout the overall follow-up period of 12 months.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prevalent hemodialysis patients treated who receive three hemodialysis treatments per week.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated by study patient and investigator/authorized&#xD;
             physician&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Ability to understand the nature and requirements of the study&#xD;
&#xD;
          -  ESKD patients on maintenance hemodialysis with a minimum of 4hrs three times a week at&#xD;
             the time of recruitment and a dialysis vintage ≥3 months in NC clinics&#xD;
&#xD;
          -  Patients fully vaccinated (2 doses) against COVID-19 with either Comirnaty (Portugal)&#xD;
             or Sputnik V (Russia) as detailed in the manufacturer's instructions&#xD;
&#xD;
          -  Patients that are scheduled to receive a third vaccine dose&#xD;
&#xD;
               -  Portugal: Comirnaty&#xD;
&#xD;
               -  Russia: Sputnik light (Sputnik V first dose vaccine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any conditions which could interfere with the patient's ability to comply with the&#xD;
             study&#xD;
&#xD;
          -  Participation in an interventional clinical study during the preceding 30 days&#xD;
&#xD;
          -  Previous participation in the same study&#xD;
&#xD;
          -  Patients with proven current COVID-19 infection as identified by routine clinical&#xD;
             practice&#xD;
&#xD;
          -  Patient in therapy with immunosuppressive medications / immunomodulators&#xD;
&#xD;
          -  Patients who already received a third COVID-19 vaccination dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Ponce, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrocare Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstatin Gurevich, ProfDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fresenius Medical Care Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr</last_name>
    <phone>+4961726085248</phone>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Braun, Dr</last_name>
    <phone>+49 6172 608 93488</phone>
    <email>Jennifer.Braun@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NephroCare Amadora</name>
      <address>
        <city>Amadora</city>
        <zip>2700-391</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>João Cruz, Dr</last_name>
      <email>joao.cruz@fmc-ag.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NephroCare Restelo</name>
      <address>
        <city>Lisboa</city>
        <zip>1400-195</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrícia Branco, Dr</last_name>
      <email>patricia.branco@fmc-ag.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NephroCare Lumiar</name>
      <address>
        <city>Lisboa</city>
        <zip>1750-130</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro Ponce, Dr</last_name>
      <email>pedro.ponce@fmc-ag.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NephroCare Vila Franca de Xira</name>
      <address>
        <city>Vila Franca De Xira</city>
        <zip>2600-076</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Aníbal Ferreira, Dr</last_name>
      <email>anibal.ferreira@fmc-ag.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Immune responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

